文献速递主动脉疾病

Anaconda支架移植物行择期EVAR的单中心271例结局

Outcomes of Endovascular Aneurysm Repair Using the Anaconda Stent-Graft.
PubMed 文献 · J Endovasc Ther · 2020-01-01

单中心回顾性研究纳入271例(平均71.5岁,260例男性)接受Anaconda支架移植物择期EVAR的腹主动脉瘤患者,中位瘤径58mm。技术成功率99.6%,30天动脉瘤相关死亡0例,中位随访72个月,动脉瘤相关死亡1.4%,再干预豁免率6年90%。

要点

  • Anaconda支架择期EVAR早期技术成功率高,30天无动脉瘤相关死亡
  • 中位随访72个月,动脉瘤相关死亡率低(1.4%),晚期并发症17.3%
  • 6年再干预豁免率90%,I型内漏率4.7%

核心结论

  • Anaconda支架移植物择期EVAR的早期和晚期结果满意,动脉瘤相关死亡率低。

研究设计与样本

  • 单中心回顾性研究,2006年1月至2017年1月纳入271例择期EVAR的腹主动脉瘤患者(平均年龄71.5岁,260例男性),中位瘤径58mm(范围50-90mm),均符合2003版IFU解剖条件。

主要发现

  • 支架植入成功率100%,首要和次要技术成功率分别为99.6%和100%。
  • 30天内3例(1.1%)死于非动脉瘤相关原因,15例(5.5%)发生围手术期并发症。
  • 中位随访72个月(范围14-141个月),I型内漏总发生率4.7%(近端11例,远端2例)。
  • 晚期动脉瘤相关并发症48例(17.3%),动脉瘤相关死亡4例(1.4%),非动脉瘤相关死亡57例(21.0%)。
  • 再干预豁免率1年95.2%、2年98%、6年90%;第二、三代装置肢体移植物闭塞率无显著差异。

临床怎么用

  • Anaconda支架可用于解剖符合2003版IFU的择期腹主动脉瘤EVAR,早期技术成功率高且动脉瘤相关死亡率低。

局限性

  • 单中心回顾性设计,随访期间使用不同代装置,解剖条件基于2003版IFU。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To report outcomes of elective endovascular aneurysm repair (EVAR) using the Anaconda stent-graft in a tertiary vascular center. Materials and Methods: A retrospective study was conducted of 271 patients (mean age 71.5 years; 260 men) who underwent elective EVAR for abdominal aortic aneurysm using the Anaconda stent-graft from January 2006 to January 2017. Median aneurysm diameter was 58 mm (range 50-90). All patients were anatomically suitable for EVAR according to the 2003 version of the instructions for use. Follow-up included computed tomography angiography at 1, 6, and 12 months and yearly thereafter for the first 4 years and then every 2 years. Primary outcomes included technical success and 30-day aneurysm-related mortality and complications; secondary outcomes were overall and aneurysm-related mortality and aneurysm-related morbidity in follow-up. Results: The Anaconda stent-graft was implanted successfully in all patients. Primary and secondary technical success rates were 99.6% and 100%, respectively. Three patients (1.1%) died within 30 days of causes unrelated to the aneurysm, while 15 patients (5.5%) suffered perioperative complications. Median follow-up was 72 months (range 14-141). The overall type I endoleak rate was 4.7% (11 proximal, 2 distal). Late aneurysm-related complications were observed in 48 patients (17.3%); aneurysm-related mortality was 1.4% (n=4). Non-aneurysm-related mortality was 21.0% (n=57). Freedom from reintervention was 95.2% at 1 year, 98% at 2 years, and 90% at 6 years. There was no significant difference in the overall limb graft occlusion rate between the second- and third-generation devices. Conclusion: Results in our cohort study demonstrate that the Anaconda stent-graft has satisfactory early and late results with low aneurysm-related mortality.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tigkiropoulos K, Stavridis K, Lazaridis I, et al. Outcomes of Endovascular Aneurysm Repair Using the Anaconda Stent-Graft. J Endovasc Ther. 2020. PMID: 32517558. doi:10.1177/1526602820918875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。